In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study

Haematologica. 2004 May;89(5):634-6.

Abstract

Eight elderly patients with relapsed or refractory acute myeloid leukemia were treated sequentially with recombinant human granulocyte colony-stimulating factor with rhG-CSF and Mylotarg. Priming with rhG-CSF in vivo induced an increase in the proportion of CD33+ cycling blasts. Four patients (50% ) achieved a complete remission, 2 patients had a partial remission and the other 2 were resistant.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aminoglycosides / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD / immunology
  • Drug Therapy, Combination
  • Gemtuzumab
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Immunotoxins / therapeutic use*
  • Leukemia, Myeloid / drug therapy*
  • Leukemia, Myeloid / immunology
  • Pilot Projects

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Immunotoxins
  • Granulocyte Colony-Stimulating Factor
  • Gemtuzumab